KBC Group’s Palvella Therapeutics PVLA Stock Holding History

KBC Group’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34K	Hold	224	–	–	﹤0.01%	1809
2026 Q1	$28K	Buy	+224	New	+$23.4K	﹤0.01%	1811

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

KBC Group's PVLA Position: Q2 2026 in Review

KBC Group held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 224 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

KBC Group first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

KBC Group held 224 shares of Palvella Therapeutics worth $34K as of Q2 2026.
KBC Group left its Palvella Therapeutics share count unchanged in Q2 2026.
Palvella Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1809 holding.
KBC Group first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.